Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2000-02-29
2003-12-02
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S012200, C530S300000, C530S350000
Reexamination Certificate
active
06656461
ABSTRACT:
Throughout this application, various publications are cited by reference numbers. Full citations for these publications may be found listed at the end of the specification immediately preceding the claims. Certain references and publications are cited by full citation. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
BACKGROUND OF THE INVENTION
Chronic obstructive pulmonary disease (COPD), consisting of emphysema and chronic bronchitis, is the fourth leading cause of death in the United States (1). Approximately 15 million Americans are affected by COPD and there is an increasing incidence in women(2). Smoking is the major risk factor for COPD and accounts for over 90% of cases seen worldwide. Despite the importance of the disease, there are no specific therapies available to limit or prevent the slow, progressive, destructive changes observed in COPD(3).
Currently the major hypothesis for the pathogenesis of emphysema is the protease-antiprotease theory(4,5). This model suggests that an imbalance between the levels of extracellular matrix degrading enzymes and their respective inhibitors damage the connective tissue matrix components of the lung. Studies over the past 30 years have demonstrated differences in the protease levels in the lung of patients with emphysema when compared to normal lung tissue(6). However, the molecular consequences of this finding have not been determined.
Although studies have demonstrated loss of the extracellular matrix in the lung of patients with emphysema, an investigation as to whether cell death contributes to the pathogenesis of this disease has not been performed.
SUMMARY OF THE INVENTION
The present invention provides a method of treating or preventing a chronic obstructive pulmonary disease in a subject, comprising administering to said subject an amount of an agent effective to inhibit apoptosis of the subject's lung cells and thus treat or prevent chronic obstructive pulmonary disease in the subject. The present invention provides for a method of identifying a compound effective to treat or prevent a chronic obstructive pulmonary disease, comprising (a) contacting lung cells from a subject having a chronic obstructive pulmonary disease with the compound and measuring the level of apoptosis of the lung cells in the presence of said compound, (b) measuring the level of apoptosis of the lung cells from the same subject in the absence of said compound, (c) comparing the level of apoptosis in step (a) with the level of apoptosis in step (b), wherein a higher level of apoptosis in step (a) indicate that the compound is effective to treat or prevent chronic obstructive pulmonary disease.
REFERENCES:
patent: 5824551 (1998-10-01), Damme et al.
Yasuda et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respiratory Medicine, (Aug. 1998) 92(8) 993-9.*
Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med. Nov 1999; 160(5 Pt 2):S5-11.*
Vignola et al. Evaluationm of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic brochitis. Journal of Allergy and Clinical Immunology, (Apr. 1999) 103 (4) 563-73.*
Goya et al. Identificaiton of CCR8 as the specific receptor for the human beta-chemokine 1-309: cloning and molecular characterization of murine CCR8 as the receptor to TCA-3. J Immunol. Feb. 1998 15; 160(4):1975-81.*
Murdoch et al. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000 May 15; 95(10):3032-43.*
Melkonyan et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A. Dec. 1997 9;94(25):13636-41.*
Imai et al. Activation of an embryonic gene product in pulmonary emphysema: identification of the secreted frizzled-related protein. Chest. May 2000; 117(5 Suppl 1):229S.*
Proost et al. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol. Jan. 1996;59(1):67-74.*
Cardone MH, et al.: Regulation of Cell Death Protease Caspase-9 by Phosphorylation.Science.vol. 282, No. 5392, Nov. 13, 1998, pp. 1318-1321 (Exhibit 2).
D'Armiento J, et al.: Collagenase Expression in the Lungs of Transgenic Mice Causes Pulmonary Emphysema.Cell.vol. 71, No. 6, Dec. 11, 1992, pp. 955-961 (Exhibit 3).
Dale TC: Signal transduction by the Wnt family of ligands.Biochem. J.(1998), vol. 329, pp. 209-223 (Exhibit 4).
Dunnill MS, et al.: Quantitative Methods In The Study Of Pulmonary Pathology.Thorax.vol. 17, 1962, pp. 320-328 (Exhibit 5).
Feinleib M, et al.: Trends in COPD Morbidity and Mortality in the United States.Am. Rev. Respir. Dis.vol. 140, No. 3, Pt. 2, Sep. 1989, pp. S9-S18 (Exhibit 6).
Finch, PW, et al.: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action.Proc. Natl. Acad. Sci. USA.vol. 94, Jun. 24, 1997, pp. 6770-6775 (Exhibit 7).
Frisch SM and Ruoslahti E: Integrins and Anoikis.Curr. Opin. in Cell Biol.vol. 9, No. 5, Oct. 1997, pp. 701-706 (Exhibit 8).
From the centers for disease control and prevention: Mortality Patterns-United States, 1991.JAMA.vol. 270, No. 24, Dec. 22, 1993, pp. 2916-2917 (Exhibit 9).
Granville DJ, et al.: Apoptosis: Molecular Aspects of Cell Death and Disease.Lab. Invest.vol. 78, No. 8, Aug. 1998, pp. 893-913 (Exhibit 10).
Hautamaki RD, et al.: Requirement of macrophage elastase for cigarette smoke-induced emphysema in mice.Science.vol. 277, Sep. 26, 1997, pp. 2002-2004 (Exhibit 11).
Hoang B, et al.: Primary structure and tissue distribution of FRZB, a novel protein related to Drosophilia frizzled, suggest a role in skeletal morphogenesis.J Biol Chem.vol. 271, No. 42, Oct. 18, 1996, pp. 26131-26137 (Exhibit 12).
Hoidal JR and Niewoehner DE: Pathogenesis of Emphysema.Chest.vol. 83, No. 4, Apr. 1983, pp. 679-685 (Exhibit 13).
Imai K and D'Armiento J: Activation of an Embryonic Gene Product in Pulmonary Emphysema.Am. Rev. Resp. Crit. Care Med.vol. 159, 1983, p. A817 (Exhibit 14).
Imai K, et al.: Expression of Membrane-Type 1 Matrix Metalloproteinase and Activation of Progelatinase A in Human Osetoarthritic Cartilage.Am. J. Pathol.vol. 151, No. 1, Jul. 1997, pp. 245-256 (Exhibit 15).
Leyns L, et al.: Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer.Cellvol. 88, No. 6, Mar. 21, 1997, pp. 747-756 (Exhibit 16).
Luisetti M, et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trialEur. Resp. J.vol. 9, No. 7, Jul. 1996, pp. 1482-1486 (Exhibit 17).
Melkonyan HS, et al.: SARPs: A family of secreted apoptosis-related proteins.Proc. Natl. Acad. Sci. USA.vol. 94, No. 25, Dec. 9, 1997, pp. 13636-13641 (Exhibit 18).
Petitclerc E, et al.: Integrin &agr;v&bgr;3Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival.Cancer Research.vol. 59, No. 11, Jun. 1, 1999, pp. 2724-2730 (Exhibit 19).
Putt F:Manual of Histopathological Staining Methods,Wiley and Sons (New York), (1972), pp. 111-126 (Exhibit 20).
Rattner A, et al.: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors.Proc Natl Acad Sci USA.vol. 94, No. 7, Apr. 1, 1997, pp. 2859-2863 (Exhibit 21).
Rudin CM and Thompson CB: Apoptosis and Disease: Regulation and Clinical Relevance of Programmed Cell Death.Annu. Rev. Med.vol. 48, 1997, pp. 267-281 (Exhibit 22).
Shapiro SD: The Pathogenesis of Emphysema: the Elastase: Antielastase Hypothesis 30 years later.Proc. Ass. Amer. Phys.vol. 107, No. 3, Oct. 1995, pp. 346-352 (Exhibit 23).
Snider GL: Chronic Obstructive Pulmonary Disease: Risk Factors, Pathophysiology and Pathogenesis.Annu. Rev. Med.vol. 40, 1989, pp. 411-429 (Exhibit 24).
Snider GL, et al.: Pitfalls in Antiprotease Therapy
D'Armiento Jeanine
Imai Kazushi
Cooper & Dunham LLP
Romeo David S.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Therapeutic treatment of chronic obstructive pulmonary disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment of chronic obstructive pulmonary disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment of chronic obstructive pulmonary disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3119869